LOS ANGELES — The novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) centanafadine (Otsuka Pharmaceutical Co., Ltd.) is effective and “clinically meaningful” for adult attention-deficit/hyperactivity disorder (ADHD), new research suggested. In a combined analysis of two phase 3 trials with a total of 859 adults, more patients who received the NDSRI had at least an 18-point improvement at week 6 on the ADHD Investigator Symptom Rating Scale (AISRS) total scores compared with patients on placebo.